News from SGC

Posted on Monday 17th of July 2017

In this piece posted on WIRED on July 17th 2017, Menaka Wilhelm describes the reasons why SGC has chosen to practice "extreme openness" in drug design by sharing data and research material with the world. This open approach is supported by SGC's pharma partners, the pharmaceutical companies that fund and collaborate with the SGC, and by SGC's public funders who collectively recognize the value of open-source science in speeding up drug discovery and ultimately developing new medicines to save patients' lives.

Posted on Friday 16th of June 2017

June 16th, 2017- SGC’s Target Enabling Package (TEP) Evaluation Group has approved five new TEPs for protein targets related to cancer, metabolic diseases and neuropsychiatric disorders.

TEPs enable scientists to research understudied proteins that have been genetically linked to human disease. The SGC generates and disseminates structural data, assays and other key research information and tools on these proteins to the scientific community.

The five TEPs recently released focus on the following genes:

Posted on Tuesday 25th of April 2017

Scientists have utilised Diamond Light Source to develop a new method to extract previously hidden information from the X-ray diffraction data that are measured when resolving the three-dimensional (3D) atomic structures of proteins and other biological molecules.

Posted on Tuesday 28th of March 2017
Posted on Tuesday 21st of March 2017

The international research consortium SGC and SciLifeLab aim to give researchers access to well-validated research tool antibodies.

[by Susanne Gräslund, SGC Karolinska, Helena Persson Lotsholm,DDDP SciLifeLab, Per I Arvidsson, Director DDDP SciLifeLab, Mikael Sundström, Director SGC European activities]

Posted on Monday 30th of January 2017

SGC and Abbvie scientists have published a research article in Nature Chemical Biology reporting a chemical probe for embryonic ectoderm development (EED) protein. The open-access probe, A-395, binds to EED inhibiting protein-protein interaction and inactivating the Polycomb repressive complex 2 (PRC2). PRC2 is dysregulated in many cancers and is a potential target for therapy.

Earlier this month, SGC and Abbvie reported on another collaboration resulting in A-196, a first-in-class open-access inhibitor against SUV4-20.

Posted on Friday 27th of January 2017

The IFOPA and FOP Friends® UK have joined together to co-fund a new study at the University of Oxford.

Alex Bullock, who established the University of Oxford FOP Research Team with Professor Jim Triffit, is optimistic that this new research technique “could lead to the development of a new class of inhibitor drug for FOP therapy.”

Posted on Monday 23rd of January 2017

In the most recent issue of Nature Chemical Biology, SGC-Toronto and Abbvie researchers share the results of their collaboration to create the first-in-class chemical probe for SUV4-20. A-196, an open access potent and selective inhibitor for SUV4-20, decreases H4K20 methylation and alters the DNA damage response, and is a useful tool to investigate the regulation of genomic integrity. 

For the Nature Chemical Biology paper: http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.2282....

Posted on Monday 23rd of January 2017

Rachel Harding, a postdoctoral fellow at SGC-Toronto, writes in this online Nature blog about her open lab notebook experiences sharing her Huntington’s disease research data in real-time.

http://blogs.nature.com/scientificdata/2016/10/19/an-open-approach-to-hu...

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03